Kane Biotech Receives FDA Approval to Increase Dosage Allowance of its revyve™ Antimicrobial Wound Gel

Rhea-AI Summary

Kane Biotech (TSX-V:KNE; OTCQB:KNBIF) has received FDA approval to increase the dosage allowance of its revyve™ Antimicrobial Wound Gel. The FDA has eliminated the previous 90 grams/month usage limitation, paving the way for the introduction of revyve™ Antimicrobial Wound Gel Spray. This new spray format is expected to be ideal for application on large wounds.

The removal of the usage restriction allows for increased use of the revyve™ product line in both prescription and over-the-counter (OTC) channels. This development is significant for Kane Biotech as it expands the potential market for their antimicrobial wound care products.

Positive

• FDA approval for increased dosage allowance of revyve™ Antimicrobial Wound Gel
• Elimination of 90 grams/month usage limitation
• Potential for expanded market reach in prescription and OTC channels
• Introduction of revyve™ Antimicrobial Wound Gel Spray for large wound applications

Negative

• None.

Paves the Way for Kane’s revyve™ Antimicrobial Wound Gel Spray

WINNIPEG, Manitoba, July 23, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”, “Kane” or the “Company”) announces that the US Food and Drug Administration (FDA) has eliminated its usage limitation on the Company’s 510(k) cleared revyve™ Antimicrobial Wound Gel (“revyve™”). Prior to the removal of this restriction, there was a 90 grams/month limit to the amount of revyve™ product that could be administered to patients.

This now clears the way for the introduction and extended use of Kane’s revyve™ Antimicrobial Wound Gel Spray which is expected to be filled in spray cans in a higher quantity making it ideal for application on large wounds.

“This is yet another important development for Kane as it allows for increased use of the revyve™ product line throughout the standard of care in both prescription and over-the- counter (OTC) channels,” said Marc Edwards, President & CEO.

About Kane Biotech

Kane Biotech Inc. is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. Kane has a portfolio of biotechnologies, intellectual property (67 patents and patents pending, trade secrets and trademarks) and products developed by Kane's own biofilm research expertise and acquired from leading research institutions. DispersinB^®, coactiv+™, coactiv+^®, DermaKB™, DermaKB Biofilm™, and revyve™ are trademarks of Kane Biotech Inc. Kane is listed on the TSX Venture Exchange under the symbol "KNE" and on the OTCQB Venture Market under the symbol “KNBIF”.

For more information:

Marc Edwards			Ray Dupuis
Chief Executive Officer			Chief Financial Officer
Kane Biotech Inc			Kane Biotech Inc
medwards@kanebiotech.com			rdupuis@kanebiotech.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Caution Regarding Forward-Looking Information
This press release contains certain statements regarding Kane Biotech Inc. that constitute forward-looking information under applicable securities law. These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, risks relating to Kane’s: (a) financial condition, including lack of significant revenues to date and reliance on equity and other financing; (b) business, including its early stage of development, government regulation, market acceptance for its products, rapid technological change and dependence on key personnel; (c) intellectual property including the ability of Kane to protect its intellectual property and dependence on its strategic partners; and (d) capital structure, including its lack of dividends on its common shares, volatility of the market price of its common shares and public company costs. Further information about these and other risks and uncertainties can be found in the disclosure documents filed by Kane with applicable securities regulatory authorities, available at www.sedarplus.ca. Kane cautions that the foregoing list of factors that may affect future results is not exhaustive.

FAQ

What FDA approval did Kane Biotech (KNBIF) receive for its revyve™ Antimicrobial Wound Gel?

Kane Biotech received FDA approval to eliminate the 90 grams/month usage limitation on its revyve™ Antimicrobial Wound Gel, allowing for increased dosage and extended use of the product.

How does the FDA approval impact Kane Biotech's (KNBIF) product line?

The FDA approval paves the way for Kane Biotech to introduce the revyve™ Antimicrobial Wound Gel Spray, which is expected to be filled in spray cans in higher quantities, making it ideal for application on large wounds.

What are the potential market implications of the FDA approval for Kane Biotech (KNBIF)?

The approval allows for increased use of the revyve™ product line throughout the standard of care in both prescription and over-the-counter (OTC) channels, potentially expanding Kane Biotech's market reach and sales opportunities.

When did Kane Biotech (KNBIF) announce the FDA approval for increased dosage allowance of revyve™?

Kane Biotech announced the FDA approval for increased dosage allowance of revyve™ Antimicrobial Wound Gel on July 23, 2024.